La Mura V, et al. - Harmful and beneficial effects of vitamin K antagonists (VKAs) in patients with portal vein thrombosis (PVT) and cirrhosis were assessed in this study. The researchers found that VKA use increased the risk of minor bleeding in patients with cirrhosis, who were given anti-coagulants for PVT compared to patients without cirrhosis who received VKA. However, this risk was offset by the ability of VKA to increase portal hypertension-related, event-free, and transplantation free-survival of patients with PVT recanalization. Portal hypertension could account for the difference in risk of major bleeding between patients with PVT vs patients with venous thromboembolism (VTE), rather than anti-coagulants.